Shionogi & Co. Overview

  • Year Founded
  • 1878

Year Founded

  • Status
  • Public

  • Employees
  • 5,489

Employees

  • Stock Symbol
  • 4507

Stock Symbol

  • Investments
  • 27

  • Share Price
  • $41.95
  • (As of Friday Closing)

Shionogi & Co. General Information

Description

Shionogi & Co Ltd is a specialty and generic drug manufacturing company. The company focuses on the manufacturing and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Shionogi engages in manufacturing, formulation, packaging, and analysis as part of its commercialization research that spans late stage drug discovery through commercial production. The company's research and development strategy utilizes partnership and licensing opportunities with academic constituents and venture companies.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Other Industries
Other Devices and Supplies
Diagnostic Equipment
Stock Exchange
TKS
Corporate Office
  • 1-8, Doshomachi 3-chome
  • Chuo-ku
  • Osaka, 541-0045
  • Japan
+81 00-0000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Shionogi & Co. Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$41.95 $41.39 $37.40 - $54.51 $11.9B 288M 1.36M $3.87

Shionogi & Co. Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2024 31-Mar-2024 FY 2023 31-Mar-2023 FY 2022 31-Mar-2022
EV 11,280,080 11,280,080 9,827,051 14,972,802
Revenue 3,011,153 3,011,153 3,151,708 2,983,161
EBITDA 1,187,855 1,187,855 1,227,403 1,127,464
Net Income 1,121,394 1,121,394 1,366,247 1,016,394
Total Assets 9,361,863 9,361,863 9,844,928 9,427,449
Total Debt 76,776 76,776 70,629 54,683
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Shionogi & Co. Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Shionogi & Co.‘s full profile, request access.

Request a free trial

Shionogi & Co. Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Shionogi & Co Ltd is a specialty and generic drug manufacturing company. The company focuses on the manufacturing and di
Pharmaceuticals
Osaka, Japan
5,489 As of 2024
00000
000000000 00000

000000

t, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et do
000000000000000
Tokyo, Japan
00000 As of 0000
00000000

000000

m dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt
0000000000000
Bengaluru, India
00000 As of 0000
000.00
00000 0000-00-00
00000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Shionogi & Co. Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Astellas Pharma Corporation Tokyo, Japan 00000 00000000
Biocon Formerly PE-Backed Bengaluru, India 00000 000.00 00000000 000.00
SynCore Biotechnology Company Corporation Yilan City, Taiwan 00
Kaken Pharmaceutical Co. Corporation Tokyo, Japan 0000 00000000
Cipla Corporation Mumbai, India 00000 000000&0
You’re viewing 5 of 11 competitors. Get the full list »

Shionogi & Co. Patents

Shionogi & Co. Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2024058212-A Use of amg517 for the treatment of autism spectrum disorders Pending 14-Oct-2022
JP-2024045832-A Medicine characterized by combining a glp-1 receptor agonist and a therapeutic agent for diseases involving anti-obesity effects Pending 22-Sep-2022
JP-2024033679-A Heterocyclic derivatives that inhibit hiv replication Pending 31-Aug-2022
JP-2024003859-A Signal processing device, cognitive function improvement system, signal processing method, and program Pending 28-Jun-2022
JP-2024003367-A Pharmaceutical composition containing a cyclic amine derivative having serotonin receptor binding activity Pending 27-Jun-2022
To view Shionogi & Co.’s complete patent history, request access »

Shionogi & Co. Executive Team (23)

Name Title Board Seat Contact Info
Nathan Mccutcheon US President, Chief Executive Officer and Board Member
Isao Teshirogi Ph.D Chief Executive Officer & Board Member
Tadashi Hara Executive Vice President & Chief Global Operations Officer
Gianine Esposito Chief Human Resources Officer
Takeki Uehara Ph.D Corporate Officer & Senior Vice President, Drug Development and Regulatory Science Division
You’re viewing 5 of 23 executive team members. Get the full list »

Shionogi & Co. Board Members (8)

Name Representing Role Since
0000000 00000 Self Board Member 000 0000
0000 000000000 00. Shionogi & Co. Chief Executive Officer & Board Member 000 0000
0000000 0000 Shionogi & Co. Outside Director 000 0000
000000 000000 Shionogi & Co. Board Member & Executive Vice President 000 0000
You’re viewing 4 of 8 board members. Get the full list »

Shionogi & Co. Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Shionogi & Co. Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Shionogi & Co.‘s full profile, request access.

Request a free trial

Shionogi & Co. Investments & Acquisitions (27)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Shionogi-Apnimed Sleep Science 31-Oct-2023 00000 0000 Other Healthcare Services
Qpex 01-Jul-2023 0000000000 00000 Drug Discovery
Lifescapes 02-Nov-2022 00000 0000 00.000 Therapeutic Devices
Pixie Dust Technologies 03-Oct-2022 00000 0000 000.00 IT Consulting and Outsourcing
Heian Shionogi 01-Aug-2022 Joint Venture Pharmaceuticals 0000 0000
You’re viewing 5 of 27 investments and acquisitions. Get the full list »

Shionogi & Co. Subsidiaries (3)

Company Name Industry Location Founded
Qpex Drug Discovery San Diego, CA 2015
Tetra Therapeutics Drug Discovery Grand Rapids, MI 0000
UMN Pharma Biotechnology Akita, Japan 0000
To view Shionogi & Co.’s complete subsidiaries history, request access »

Shionogi & Co. ESG

Risk Overview

Risk Rating

Updated May, 31, 2024

23.08 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,216

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 452

Rank

0.00

Percentile

To view Shionogi & Co.’s complete esg history, request access »

Shionogi & Co. Exits (3)

Company Name Exit Date Exit Type Exit Size Status Buyers
Pixie Dust Technologies 03-Oct-2022 00000 00000 00 000.00 Completed
  • 5 buyers
Nemesis Bioscience 15-Jun-2018 00000 00000 00 00.000 Completed
  • 6 buyers
StemRIM 15-Dec-2014 Later Stage VC 00.000 Completed
To view Shionogi & Co.’s complete exits history, request access »

Shionogi & Co. FAQs

  • When was Shionogi & Co. founded?

    Shionogi & Co. was founded in 1878.

  • Who is the CEO of Shionogi & Co.?

    Nathan Mccutcheon and Isao Teshirogi Ph.D are the CEOs of Shionogi & Co..

  • Where is Shionogi & Co. headquartered?

    Shionogi & Co. is headquartered in Osaka, Japan.

  • What is the size of Shionogi & Co.?

    Shionogi & Co. has 5,489 total employees.

  • What industry is Shionogi & Co. in?

    Shionogi & Co.’s primary industry is Pharmaceuticals.

  • Is Shionogi & Co. a private or public company?

    Shionogi & Co. is a Public company.

  • What is Shionogi & Co.’s stock symbol?

    The ticker symbol for Shionogi & Co. is 4507.

  • What is the current stock price of Shionogi & Co.?

    As of 12-Jul-2024 the stock price of Shionogi & Co. is $41.95.

  • What is the current market cap of Shionogi & Co.?

    The current market capitalization of Shionogi & Co. is $11.9B.

  • What is Shionogi & Co.’s current revenue?

    The trailing twelve month revenue for Shionogi & Co. is $3.01B.

  • Who are Shionogi & Co.’s competitors?

    Astellas Pharma, Biocon, SynCore Biotechnology Company, Kaken Pharmaceutical Co., and Cipla are some of the 11 competitors of Shionogi & Co..

  • What is Shionogi & Co.’s annual earnings per share (EPS)?

    Shionogi & Co.’s EPS for 12 months was $3.87.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »